Point72 Asset Management’s Cartesian Therapeutics RNAC Stock Holding History

Point72 Asset Management’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-33,871	Closed	-$244K	–	4381
2025 Q4	$244K	Buy	+33,871	New	+$274K	﹤0.01%	3560
2020 Q4	–	Sell	-13,333	Closed	-$992K	–	1100
2020 Q3	$992K	Sell	13,333 -20,000	-60%	-$1.53M	0.01%	779
2020 Q2	$2.84M	Buy	33,333 +4,549	+16%	+$412K	0.02%	552
2020 Q1	$2.08M	Buy	+28,784	New	+$2.78M	0.02%	500
2018 Q1	–	Sell	-3,338	Closed	-$982K	–	1094
2017 Q4	$982K	Buy	+3,338	New	+$1.46M	﹤0.01%	804
2017 Q3	–	Sell	-3,995	Closed	-$2.38M	–	1030
2017 Q2	$2.38M	Buy	+3,995	New	+$1.76M	0.01%	621

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management's RNAC Position: Q1 2026 in Review

Point72 Asset Management sold out of Cartesian Therapeutics (RNAC) in Q1 2026, closing a stake of 33,871 shares — an estimated $244K sold.

Point72 Asset Management first reported a position in RNAC in Q2 2017 and held it in 6 quarters. The position peaked at $2.84M in Q2 2020. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

Point72 Asset Management reported no remaining Cartesian Therapeutics position as of Q1 2026 after selling out during the quarter.
Point72 Asset Management sold 33,871 Cartesian Therapeutics shares in Q1 2026, an estimated $244K.
Point72 Asset Management first reported a position in Cartesian Therapeutics in Q2 2017 and held it in 6 quarters.
Point72 Asset Management's Cartesian Therapeutics position peaked at $2.84M in Q2 2020.
83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.